GlobeNewswire
Helus Pharma Appoints Michael Cola as Chief Executive Officer to Lead Next Phase of Scale and Execution
📈
AI Sentiment
Highly Positive
9/10
- Home
- HELP
HELP
Cybin Inc. Common Stock
as of 02-13-2026 3:40pm EST
$6.14
+$0.22
+3.72%
| Founded: | N/A | Country: | Canada |
| Employees: | N/A | City: | N/A |
| Market Cap: | 375.7M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 476.5K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.81 - $10.59 | Next Earning Date: | 02-13-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | -99411966.0 | FCF Growth: | N/A |
Latest Cybin Inc. Common Stock News
HELP Breaking Stock News: Dive into HELP Ticker-Specific Updates for Smart Investing
Compare HELP vs Leading Stocks
See how HELP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "HELP Cybin Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.